(EL42) Deka MSCI Europe - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: DE000ETFL284 • Europe Large-Cap Blend Equity
EL42: Stocks, Bonds, Equities, European
The Deka MSCI Europe UCITS ETF (Ticker: EL42), listed on XETRA, is a large-cap blend equity fund designed to track the performance of developed European markets. It leverages the Morningstar DM Eur TME NR EUR index, ensuring broad diversification across key European economies. This ETF is particularly suited for investors seeking exposure to Europes established companies, balancing value and growth opportunities.
With an AUM of approximately €1.064 billion, this fund demonstrates significant scale, which often leads to lower tracking error and higher liquidity. The expense ratio, while not explicitly mentioned, is typically competitive for ETFs in this category, making it an efficient choice for cost-conscious investors. The fund employs a physical replication strategy, meaning it holds the underlying securities, which can appeal to those prioritizing transparency and direct market exposure.
Geographically, the ETF spans across major European markets, including the UK, France, Germany, and Switzerland, providing a well-rounded exposure to the regions economic landscape. Sector-wise, it maintains a balanced portfolio, with allocations to sectors such as financials, industrials, and consumer goods, reflecting the diversity of Europes large-cap equities. This diversification helps mitigate risk and captures growth across various industries.
Investors should consider the ETFs tracking error and how closely it mirrors its benchmark. Historical data indicates that the fund has maintained a tight tracking relative to its index, a testament to its effective management. Additionally, the funds performance can be influenced by currency fluctuations, as it does not employ currency hedging, which is a critical factor for investors holding non-euro denominated portfolios.
For fund managers, the ETFs large-cap focus aligns with a buy-and-hold strategy, offering stability and reduced turnover. Its liquidity and scale make it an attractive option for both retail and institutional investors seeking efficient European market exposure. The funds structure and performance metrics underscore its role as a core holding in a diversified portfolio aiming for long-term growth in the European market.
Additional Sources for EL42 ETF
EL42 ETF Overview
Market Cap in USD | 1,152m |
Category | Europe Large-Cap Blend Equity |
IPO / Inception | 2009-06-09 |
EL42 ETF Ratings
Growth 5y | 75.2% |
Fundamental | - |
Dividend | 53.2% |
Rel. Strength | 2.72 |
Analysts | - |
Fair Price Momentum | 18.86 EUR |
Fair Price DCF | - |
EL42 Dividends
Dividend Yield 12m | 2.52% |
Yield on Cost 5y | 4.74% |
Annual Growth 5y | 11.60% |
Payout Consistency | 90.5% |
EL42 Growth Ratios
Growth Correlation 3m | 77.8% |
Growth Correlation 12m | 58.8% |
Growth Correlation 5y | 91.4% |
CAGR 5y | 13.89% |
CAGR/Max DD 5y | 0.71 |
Sharpe Ratio 12m | 1.16 |
Alpha | 1.33 |
Beta | 0.990 |
Volatility | 12.86% |
Current Volume | 66.3k |
Average Volume 20d | 47.4k |
As of March 31, 2025, the stock is trading at EUR 18.37 with a total of 66,251 shares traded.
Over the past week, the price has changed by -1.11%, over one month by -2.54%, over three months by +8.08% and over the past year by +9.38%.
Yes. Based on ValueRay Analyses, Deka MSCI Europe (XETRA:EL42) is currently (March 2025) a good stock to buy. It has a ValueRay Growth Rating of 75.16 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EL42 as of March 2025 is 18.86. This means that EL42 is currently overvalued and has a potential downside of 2.67%.
Deka MSCI Europe has no consensus analysts rating.
According to ValueRays Forecast Model, EL42 Deka MSCI Europe will be worth about 21 in March 2026. The stock is currently trading at 18.37. This means that the stock has a potential upside of +14.1%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 21 | 14.1% |